Skip to main content
. 2024 Oct 16;26(10):euae252. doi: 10.1093/europace/euae252

Graphical Abstract.

Graphical Abstract

Class III antiarrhythmic drugs are capable of inhibiting SARS-CoV-2 ORF 3a-mediated cation currents, thus offering novel therapeutic avenues for the management of cardiac arrhythmias associated with COVID-19. Created with the help of DALL-E 2, OpenAI.